

**Sexually  
Transmitted  
Disease  
Surveillance  
2022:  
Enhanced Gonococcal Isolate  
Surveillance Project  
Site-Specific Profiles**

**Division of STD Prevention  
April 2024**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
CENTERS FOR DISEASE CONTROL AND PREVENTION  
NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STD, AND TB PREVENTION  
DIVISION OF STD PREVENTION  
ATLANTA, GEORGIA 30329-4027**

## Acknowledgments

Publication of this report would not have been possible without the contributions of all participating state and local health departments, sexually transmitted disease clinics, public health laboratories, and regional laboratories.

This report was prepared by:

Sammie Haskin, Alesia Harvey, Rebekah Frankson, LaShondra Berman, Kristen Kreisel, and Luke Shouse, Surveillance and Data Science Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Additional contributions by Matthew Schmerer, Myriam Bélanger, and Ellen Kersh, STD Laboratory Reference and Research Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

## Copyright Information

All material contained in this report is in the public domain and may be used and reprinted without special permission; however, citation as to source is appreciated.

## Suggested Citation

Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance 2022: Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles*. Atlanta: U.S. Department of Health and Human Services; 2024.

## Web Site

The online version of this report is available at <https://www.cdc.gov/std/statistics/gisp-profiles/default.htm>.

## Technical Note

Antimicrobial susceptibility data presented in this report are based on criteria established by the Clinical & Laboratory Standards Institute (CLSI).

**2022 Enhanced Gonococcal Isolate Surveillance Project**  
**Clinical Sites and Years Participated**

Columbus, Ohio <i>(2018–2022)</i>	Philadelphia, Pennsylvania <i>(2018–2022)</i>
Las Vegas, Nevada <i>(2018–2022)</i>	Phoenix, Arizona <i>(2020–2022)</i>
New Orleans, Louisiana <i>(2018–2022)</i>	Pontiac, Michigan <i>(2018–2022)</i>
Orange County, California <i>(2018–2022)</i>	San Diego, California <i>(2018–2022)</i>

**2022 Enhanced Gonococcal Isolate Surveillance Project**  
**Regional Laboratories**

Maryland Department of Health and Mental Hygiene <i>Baltimore, Maryland</i>
Tennessee Department of Health <i>Nashville, Tennessee</i>
Utah Department of Health <i>Salt Lake City, Utah</i>
Washington State Department of Health <i>Seattle, Washington</i>

**2022 Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles**  
**Table of Contents**

Las Vegas, Nevada..... 6-15

New Orleans, Louisiana..... 16-25

Orange County, California..... 26-35

Philadelphia, Pennsylvania..... 36-45

Phoenix, Arizona..... 46-55

Pontiac, Michigan..... 56-65


San Diego, California..... 66-75

**2022 Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles**  
**List of Figures**

For each participating site of the 2022 Enhanced Gonococcal Isolate Surveillance Project, the following figures are presented:

- Figure A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2022
- Figure B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2022
- Figure C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2020–2022
- Figure D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2020–2022
- Figure E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2020–2022
- Figure F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2020–2022
- Figure G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2020–2022
- Figure H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2020–2022
- Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2020–2022
- Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2020–2022


Figure A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2022



Site of Infection	Patient Gender	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	16 (9.0)	31 (17.5)	25 (14.1)	50 (28.2)	21 (11.9)	12 (6.8)	7 (4.0)	3 (1.7)	7 (4.0)	4 (2.3)	1 (0.6)	177
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	2 (8.7)	7 (30.4)	2 (8.7)	6 (26.1)	0 (0)	5 (21.7)	1 (4.3)	0 (0)	0 (0)	0 (0)	0 (0)	23
Pharyngeal	Female	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2
Rectal	Male	2 (9.1)	8 (36.4)	5 (22.7)	4 (18.2)	2 (9.1)	1 (4.5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	22
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1

Cases with unknown age were excluded.


Figure B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2022



Site of Infection	Patient Gender	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	5 (2.8)	95 (53.7)	1 (0.6)	26 (14.7)	40 (22.6)	4 (2.3)	6 (3.4)	177
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	1 (4.3)	7 (30.4)	0 (0)	3 (13.0)	10 (43.5)	1 (4.3)	1 (4.3)	23
Pharyngeal	Female	0 (0)	0 (0)	1 (50.0)	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	2
Rectal	Male	0 (0)	1 (4.5)	2 (9.1)	0 (0)	4 (18.2)	14 (63.6)	0 (0)	1 (4.5)	22
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	1

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Figure C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2020-2022




Site of Infection	Year	MSM	MSW	Women	Total
Genital	2020	59	105	6	170
Genital	2021	48	117	1	166
Genital	2022	47	129	0	176
Pharyngeal	2020	22	12	4	38
Pharyngeal	2021	10	7	4	21
Pharyngeal	2022	14	9	2	25
Rectal	2020	19	0	3	22
Rectal	2021	10	0	0	10
Rectal	2022	21	0	1	22

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.



Figure D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2020-2022



Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	117 (67.2)	38 (21.8)	11 (6.3)	8 (4.6)	0 (0.0)	0 (0.0)	0 (0.0)	174
Genital	2021	118 (70.2)	34 (20.2)	8 (4.8)	7 (4.2)	1 (0.6)	0 (0.0)	0 (0.0)	168
Genital	2022	116 (65.5)	49 (27.7)	5 (2.8)	7 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	177
Pharyngeal	2020	25 (61.0)	9 (22.0)	7 (17.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	41
Pharyngeal	2021	7 (31.8)	10 (45.5)	3 (13.6)	2 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	22
Pharyngeal	2022	12 (48.0)	8 (32.0)	3 (12.0)	2 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	25
Rectal	2020	16 (69.6)	1 (4.3)	3 (13.0)	3 (13.0)	0 (0.0)	0 (0.0)	0 (0.0)	23
Rectal	2021	5 (45.5)	5 (45.5)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	15 (65.2)	7 (30.4)	0 (0.0)	1 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	23


GISP Alert Value = cefixime MIC  $\geq 0.25$  µg/mL; CLSI Non-susceptible = cefixime MIC  $\geq 0.5$  µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Figure E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2020-2022



Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	132 (75.9)	36 (20.7)	5 (2.9)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	174
Genital	2021	93 (55.4)	60 (35.7)	13 (7.7)	2 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	168
Genital	2022	120 (67.8)	54 (30.5)	3 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	177
Pharyngeal	2020	33 (80.5)	7 (17.1)	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	41
Pharyngeal	2021	8 (36.4)	10 (45.5)	4 (18.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	22
Pharyngeal	2022	17 (68.0)	6 (24.0)	2 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25
Rectal	2020	18 (78.3)	4 (17.4)	0 (0.0)	1 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23
Rectal	2021	5 (45.5)	2 (18.2)	4 (36.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	17 (73.9)	5 (21.7)	1 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23


GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Figure F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2020-2022



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2020	29 (16.7)	88 (50.6)	32 (18.4)	22 (12.6)	3 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	174
Genital	2021	26 (15.5)	103 (61.3)	14 (8.3)	14 (8.3)	11 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	168
Genital	2022	38 (21.5)	88 (49.7)	19 (10.7)	30 (16.9)	1 (0.6)	0 (0.0)	1 (0.6)	0 (0.0)	177
Pharyngeal	2020	6 (14.6)	17 (41.5)	6 (14.6)	8 (19.5)	1 (2.4)	0 (0.0)	3 (7.3)	0 (0.0)	41
Pharyngeal	2021	2 (9.1)	15 (68.2)	3 (13.6)	2 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	22
Pharyngeal	2022	4 (16.0)	8 (32.0)	3 (12.0)	9 (36.0)	0 (0.0)	0 (0.0)	1 (4.0)	0 (0.0)	25
Rectal	2020	6 (26.1)	11 (47.8)	1 (4.3)	4 (17.4)	0 (0.0)	0 (0.0)	1 (4.3)	0 (0.0)	23
Rectal	2021	2 (18.2)	6 (54.5)	0 (0.0)	0 (0.0)	3 (27.3)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	1 (4.3)	11 (47.8)	5 (21.7)	6 (26.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23


GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; CLSI Non-susceptible = azithromycin MIC ≥2.0 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established an azithromycin resistance breakpoint for *N. gonorrhoeae*.

Figure G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	1 (0.9)	0 (0.0)	1
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
 Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	2 (3.4)	1 (1.0)	0 (0.0)	3
Genital	2021	7 (14.6)	4 (3.4)	0 (0.0)	11
Genital	2022	1 (2.1)	1 (0.8)	0 (0.0)	2
Pharyngeal	2020	2 (9.1)	1 (8.3)	1 (25.0)	4
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	1 (7.1)	0 (0.0)	0 (0.0)	1
Rectal	2020	1 (5.3)	0 (0.0)	0 (0.0)	1
Rectal	2021	3 (30.0)	0 (0.0)	0 (0.0)	3
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MIC  $\geq 2.0 \mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	27 (45.8)	32 (30.5)	3 (50.0)	62
Genital	2021	18 (37.5)	40 (34.2)	1 (100.0)	59
Genital	2022	22 (46.8)	28 (21.7)	0 (0.0)	50
Pharyngeal	2020	7 (31.8)	0 (0.0)	2 (50.0)	9
Pharyngeal	2021	5 (50.0)	2 (28.6)	1 (25.0)	8
Pharyngeal	2022	8 (57.1)	0 (0.0)	1 (50.0)	9
Rectal	2020	9 (47.4)	0 (0.0)	0 (0.0)	9
Rectal	2021	4 (40.0)	0 (0.0)	0 (0.0)	4
Rectal	2022	4 (19.0)	0 (0.0)	1 (100.0)	5

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MIC ≥1.0 µg/mL.

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2022




Site of Infection	Patient Gender	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	3 (4.5)	15 (22.7)	12 (18.2)	13 (19.7)	6 (9.1)	7 (10.6)	4 (6.1)	4 (6.1)	1 (1.5)	1 (1.5)	0 (0)	66
Genital	Female	0 (0)	0 (0)	0 (0)	3 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3
Pharyngeal	Male	0 (0)	1 (10.0)	3 (30.0)	4 (40.0)	2 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	10
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	3 (33.3)	2 (22.2)	4 (44.4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	9
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.




Figure B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2022



Site of Infection	Patient Gender	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	1 (1.5)	4 (6.1)	43 (65.2)	0 (0)	16 (24.2)	2 (3.0)	0 (0)	0 (0)	66
Genital	Female	0 (0)	0 (0)	1 (33.3)	0 (0)	2 (66.7)	0 (0)	0 (0)	0 (0)	3
Pharyngeal	Male	0 (0)	0 (0)	3 (30.0)	0 (0)	7 (70.0)	0 (0)	0 (0)	0 (0)	10
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	3 (33.3)	1 (11.1)	0 (0)	5 (55.6)	0 (0)	0 (0)	0 (0)	9
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2020-2022



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2020	22	64	3	89
Genital	2021	41	33	1	75
Genital	2022	42	24	0	66
Pharyngeal	2020	5	1	0	6
Pharyngeal	2021	13	1	1	15
Pharyngeal	2022	7	3	0	10
Rectal	2020	5	2	0	7
Rectal	2021	3	1	0	4
Rectal	2022	9	0	0	9

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2020-2022



Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	65 (71.4)	22 (24.2)	2 (2.2)	2 (2.2)	0 (0.0)	0 (0.0)	0 (0.0)	91
Genital	2021	57 (74.0)	13 (16.9)	6 (7.8)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	77
Genital	2022	48 (68.6)	12 (17.1)	6 (8.6)	4 (5.7)	0 (0.0)	0 (0.0)	0 (0.0)	70
Pharyngeal	2020	5 (83.3)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	6
Pharyngeal	2021	13 (86.7)	1 (6.7)	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	15
Pharyngeal	2022	8 (80.0)	2 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2020	4 (57.1)	3 (42.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7
Rectal	2021	3 (75.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2022	6 (60.0)	4 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10


GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Figure E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2020-2022



Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	53 (58.2)	32 (35.2)	4 (4.4)	2 (2.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	91
Genital	2021	59 (76.6)	16 (20.8)	1 (1.3)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	77
Genital	2022	43 (61.4)	25 (35.7)	2 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	70
Pharyngeal	2020	4 (66.7)	0 (0.0)	2 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Pharyngeal	2021	11 (73.3)	4 (26.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	15
Pharyngeal	2022	7 (70.0)	3 (30.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2020	4 (57.1)	3 (42.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7
Rectal	2021	3 (75.0)	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2022	6 (60.0)	3 (30.0)	1 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10


GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Figure F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2020-2022



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2020	19 (20.9)	39 (42.9)	7 (7.7)	14 (15.4)	12 (13.2)	0 (0.0)	0 (0.0)	0 (0.0)	91
Genital	2021	5 (6.5)	42 (54.5)	12 (15.6)	9 (11.7)	9 (11.7)	0 (0.0)	0 (0.0)	0 (0.0)	77
Genital	2022	13 (18.6)	31 (44.3)	13 (18.6)	8 (11.4)	4 (5.7)	1 (1.4)	0 (0.0)	0 (0.0)	70
Pharyngeal	2020	0 (0.0)	4 (66.7)	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Pharyngeal	2021	1 (6.7)	8 (53.3)	1 (6.7)	4 (26.7)	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	15
Pharyngeal	2022	3 (30.0)	3 (30.0)	0 (0.0)	2 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (20.0)	10
Rectal	2020	1 (14.3)	4 (57.1)	0 (0.0)	1 (14.3)	0 (0.0)	1 (14.3)	0 (0.0)	0 (0.0)	7
Rectal	2021	0 (0.0)	2 (50.0)	0 (0.0)	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2022	1 (10.0)	4 (40.0)	1 (10.0)	1 (10.0)	1 (10.0)	0 (0.0)	0 (0.0)	2 (20.0)	10


GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; CLSI Non-susceptible = azithromycin MIC ≥2.0 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established an azithromycin resistance breakpoint for *N. gonorrhoeae*.

Figure G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	1 (2.4)	0 (0.0)	0 (0.0)	1
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
 Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	1 (4.5)	11 (17.2)	0 (0.0)	12
Genital	2021	6 (14.6)	2 (6.1)	0 (0.0)	8
Genital	2022	4 (9.5)	1 (4.2)	0 (0.0)	5
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	1 (100.0)	0 (0.0)	1
Pharyngeal	2022	2 (28.6)	0 (0.0)	0 (0.0)	2
Rectal	2020	1 (20.0)	0 (0.0)	0 (0.0)	1
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	3 (33.3)	0 (0.0)	0 (0.0)	3

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
 Azithromycin elevated MIC  $\geq 2.0 \mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.



Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	10 (45.5)	24 (37.5)	1 (33.3)	35
Genital	2021	11 (26.8)	15 (45.5)	1 (100.0)	27
Genital	2022	14 (33.3)	10 (41.7)	0 (0.0)	24
Pharyngeal	2020	2 (40.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	2021	4 (30.8)	0 (0.0)	0 (0.0)	4
Pharyngeal	2022	4 (57.1)	0 (0.0)	0 (0.0)	4
Rectal	2020	2 (40.0)	1 (50.0)	0 (0.0)	3
Rectal	2021	1 (33.3)	1 (100.0)	0 (0.0)	2
Rectal	2022	4 (44.4)	0 (0.0)	0 (0.0)	4

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MIC ≥1.0 µg/mL.

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.


Figure A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2022



Site of Infection	Patient Gender	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	3 (2.6)	8 (6.8)	26 (22.2)	37 (31.6)	15 (12.8)	10 (8.5)	5 (4.3)	6 (5.1)	3 (2.6)	3 (2.6)	1 (0.9)	117
Genital	Female	2 (15.4)	1 (7.7)	3 (23.1)	3 (23.1)	1 (7.7)	2 (15.4)	0 (0)	0 (0)	1 (7.7)	0 (0)	0 (0)	13
Pharyngeal	Male	0 (0)	9 (14.1)	20 (31.3)	14 (21.9)	6 (9.4)	5 (7.8)	8 (12.5)	0 (0)	1 (1.6)	0 (0)	1 (1.6)	64
Pharyngeal	Female	0 (0)	0 (0)	1 (14.3)	2 (28.6)	1 (14.3)	3 (42.9)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7
Rectal	Male	0 (0)	12 (12.1)	28 (28.3)	25 (25.3)	11 (11.1)	9 (9.1)	6 (6.1)	6 (6.1)	0 (0)	0 (0)	2 (2.0)	99
Rectal	Female	0 (0)	1 (25.0)	0 (0)	2 (50.0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (25.0)	0 (0)	0 (0)	4

Cases with unknown age were excluded.


Figure B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2022



Site of Infection	Patient Gender	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	13 (11.1)	0 (0)	0 (0)	25 (21.4)	60 (51.3)	0 (0)	19 (16.2)	117
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	5 (38.5)	7 (53.8)	0 (0)	1 (7.7)	13
Pharyngeal	Male	0 (0)	15 (23.4)	0 (0)	0 (0)	9 (14.1)	37 (57.8)	0 (0)	3 (4.7)	64
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	3 (42.9)	4 (57.1)	0 (0)	0 (0)	7
Rectal	Male	0 (0)	21 (21.2)	0 (0)	0 (0)	11 (11.1)	65 (65.7)	0 (0)	2 (2.0)	99
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	3 (75.0)	1 (25.0)	0 (0)	0 (0)	4

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2020-2022



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2020	84	69	6	159
Genital	2021	47	40	9	96
Genital	2022	72	44	13	129
Pharyngeal	2020	18	1	0	19
Pharyngeal	2021	32	4	5	41
Pharyngeal	2022	58	3	7	68
Rectal	2020	75	0	0	75
Rectal	2021	59	0	2	61
Rectal	2022	93	3	4	100

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2020-2022



Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	129 (75.0)	37 (21.5)	1 (0.6)	5 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	172
Genital	2021	113 (63.5)	51 (28.7)	8 (4.5)	6 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)	178
Genital	2022	84 (64.6)	34 (26.2)	5 (3.8)	7 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	130
Pharyngeal	2020	20 (76.9)	4 (15.4)	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	26
Pharyngeal	2021	46 (59.0)	26 (33.3)	0 (0.0)	6 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	78
Pharyngeal	2022	39 (51.3)	25 (32.9)	3 (3.9)	9 (11.8)	0 (0.0)	0 (0.0)	0 (0.0)	76
Rectal	2020	83 (73.5)	20 (17.7)	4 (3.5)	6 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	113
Rectal	2021	83 (58.0)	48 (33.6)	4 (2.8)	8 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	143
Rectal	2022	49 (44.1)	37 (33.3)	8 (7.2)	17 (15.3)	0 (0.0)	0 (0.0)	0 (0.0)	111


GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Figure E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2020-2022



Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	110 (64.0)	50 (29.1)	12 (7.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	172
Genital	2021	106 (59.6)	62 (34.8)	10 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	178
Genital	2022	79 (60.8)	42 (32.3)	9 (6.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	130
Pharyngeal	2020	18 (69.2)	5 (19.2)	3 (11.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	26
Pharyngeal	2021	42 (53.8)	29 (37.2)	7 (9.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	78
Pharyngeal	2022	43 (56.6)	30 (39.5)	3 (3.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	76
Rectal	2020	71 (62.8)	36 (31.9)	6 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	113
Rectal	2021	79 (55.2)	56 (39.2)	8 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	143
Rectal	2022	50 (45.0)	52 (46.8)	9 (8.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	111


GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Figure F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2020-2022



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2020	7 (4.1)	107 (62.2)	20 (11.6)	23 (13.4)	14 (8.1)	0 (0.0)	0 (0.0)	1 (0.6)	172
Genital	2021	13 (7.3)	130 (73.0)	11 (6.2)	17 (9.6)	6 (3.4)	1 (0.6)	0 (0.0)	0 (0.0)	178
Genital	2022	14 (10.8)	84 (64.6)	11 (8.5)	7 (5.4)	13 (10.0)	0 (0.0)	0 (0.0)	1 (0.8)	130
Pharyngeal	2020	3 (11.5)	12 (46.2)	7 (26.9)	3 (11.5)	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	26
Pharyngeal	2021	2 (2.6)	45 (57.7)	13 (16.7)	16 (20.5)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	78
Pharyngeal	2022	7 (9.2)	49 (64.5)	8 (10.5)	6 (7.9)	5 (6.6)	0 (0.0)	0 (0.0)	1 (1.3)	76
Rectal	2020	5 (4.4)	62 (54.9)	13 (11.5)	20 (17.7)	13 (11.5)	0 (0.0)	0 (0.0)	0 (0.0)	113
Rectal	2021	5 (3.5)	83 (58.0)	17 (11.9)	26 (18.2)	12 (8.4)	0 (0.0)	0 (0.0)	0 (0.0)	143
Rectal	2022	12 (10.8)	66 (59.5)	7 (6.3)	15 (13.5)	11 (9.9)	0 (0.0)	0 (0.0)	0 (0.0)	111


GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; CLSI Non-susceptible = azithromycin MIC ≥2.0 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established an azithromycin resistance breakpoint for *N. gonorrhoeae*.

Figure G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
 Cefixime elevated MIC  $\geq 0.25 \mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.



Figure H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
 Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	12 (14.3)	2 (2.9)	0 (0.0)	14
Genital	2021	3 (6.4)	1 (2.5)	1 (11.1)	5
Genital	2022	13 (18.1)	1 (2.3)	0 (0.0)	14
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	1 (20.0)	1
Pharyngeal	2022	6 (10.3)	0 (0.0)	0 (0.0)	6
Rectal	2020	9 (12.0)	0 (0.0)	0 (0.0)	9
Rectal	2021	10 (16.9)	0 (0.0)	0 (0.0)	10
Rectal	2022	9 (9.7)	1 (33.3)	0 (0.0)	10

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
Azithromycin elevated MIC  $\geq 2.0 \mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	34 (40.5)	25 (36.2)	2 (33.3)	61
Genital	2021	14 (29.8)	10 (25.0)	3 (33.3)	27
Genital	2022	24 (33.3)	16 (36.4)	6 (46.2)	46
Pharyngeal	2020	12 (66.7)	0 (0.0)	0 (0.0)	12
Pharyngeal	2021	8 (25.0)	0 (0.0)	1 (20.0)	9
Pharyngeal	2022	22 (37.9)	3 (100.0)	2 (28.6)	27
Rectal	2020	35 (46.7)	0 (0.0)	0 (0.0)	35
Rectal	2021	21 (35.6)	0 (0.0)	1 (50.0)	22
Rectal	2022	47 (50.5)	0 (0.0)	1 (25.0)	48

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MIC ≥1.0 µg/mL.

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.


Figure A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2022



Site of Infection	Patient Gender	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	20 (7.8)	43 (16.7)	63 (24.5)	48 (18.7)	34 (13.2)	11 (4.3)	12 (4.7)	7 (2.7)	5 (1.9)	7 (2.7)	7 (2.7)	257
Genital	Female	1 (20.0)	1 (20.0)	1 (20.0)	1 (20.0)	0 (0)	0 (0)	1 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)	5
Pharyngeal	Male	0 (0)	2 (33.3)	1 (16.7)	2 (33.3)	0 (0)	1 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	6 (17.6)	13 (38.2)	8 (23.5)	4 (11.8)	2 (5.9)	1 (2.9)	0 (0)	0 (0)	0 (0)	0 (0)	34
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.


Figure B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2022



Site of Infection	Patient Gender	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	1 (0.4)	158 (61.5)	0 (0)	21 (8.2)	18 (7.0)	28 (10.9)	31 (12.1)	257
Genital	Female	0 (0)	0 (0)	2 (40.0)	0 (0)	1 (20.0)	0 (0)	1 (20.0)	1 (20.0)	5
Pharyngeal	Male	0 (0)	0 (0)	1 (16.7)	0 (0)	4 (66.7)	0 (0)	1 (16.7)	0 (0)	6
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	2 (5.9)	9 (26.5)	0 (0)	16 (47.1)	1 (2.9)	2 (5.9)	4 (11.8)	34
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2020-2022



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2020	57	123	3	183
Genital	2021	55	151	8	214
Genital	2022	76	177	5	258
Pharyngeal	2020	9	0	0	9
Pharyngeal	2021	3	1	1	5
Pharyngeal	2022	6	0	0	6
Rectal	2020	20	1	0	21
Rectal	2021	17	0	0	17
Rectal	2022	34	0	0	34

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2020-2022



Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	149 (80.1)	27 (14.5)	10 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	186
Genital	2021	180 (82.9)	28 (12.9)	4 (1.8)	4 (1.8)	1 (0.5)	0 (0.0)	0 (0.0)	217
Genital	2022	205 (78.2)	47 (17.9)	6 (2.3)	4 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	262
Pharyngeal	2020	8 (72.7)	2 (18.2)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Pharyngeal	2021	4 (80.0)	0 (0.0)	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	5 (83.3)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Rectal	2020	15 (71.4)	5 (23.8)	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	21
Rectal	2021	14 (77.8)	1 (5.6)	1 (5.6)	2 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	18
Rectal	2022	24 (70.6)	5 (14.7)	3 (8.8)	1 (2.9)	0 (0.0)	0 (0.0)	1 (2.9)	34


GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Figure E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2020-2022



Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	154 (82.8)	29 (15.6)	2 (1.1)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	186
Genital	2021	167 (77.0)	42 (19.4)	6 (2.8)	1 (0.5)	0 (0.0)	1 (0.5)	0 (0.0)	0 (0.0)	217
Genital	2022	190 (72.5)	62 (23.7)	9 (3.4)	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	262
Pharyngeal	2020	8 (72.7)	3 (27.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Pharyngeal	2021	3 (60.0)	1 (20.0)	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	6 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Rectal	2020	18 (85.7)	3 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	21
Rectal	2021	11 (61.1)	5 (27.8)	1 (5.6)	1 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Rectal	2022	21 (61.8)	9 (26.5)	2 (5.9)	1 (2.9)	0 (0.0)	0 (0.0)	1 (2.9)	0 (0.0)	34

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.


CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.



Figure F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2020-2022



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2020	12 (6.5)	69 (37.1)	49 (26.3)	37 (19.9)	8 (4.3)	8 (4.3)	1 (0.5)	2 (1.1)	186
Genital	2021	39 (18.0)	117 (53.9)	26 (12.0)	25 (11.5)	6 (2.8)	2 (0.9)	0 (0.0)	2 (0.9)	217
Genital	2022	91 (34.7)	99 (37.8)	35 (13.4)	31 (11.8)	5 (1.9)	0 (0.0)	1 (0.4)	0 (0.0)	262
Pharyngeal	2020	0 (0.0)	6 (54.5)	2 (18.2)	1 (9.1)	2 (18.2)	0 (0.0)	0 (0.0)	0 (0.0)	11
Pharyngeal	2021	1 (20.0)	2 (40.0)	0 (0.0)	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	0 (0.0)	3 (50.0)	2 (33.3)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Rectal	2020	2 (9.5)	8 (38.1)	5 (23.8)	5 (23.8)	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	21
Rectal	2021	1 (5.6)	13 (72.2)	3 (16.7)	1 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Rectal	2022	10 (29.4)	12 (35.3)	6 (17.6)	4 (11.8)	1 (2.9)	1 (2.9)	0 (0.0)	0 (0.0)	34


GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; CLSI Non-susceptible = azithromycin MIC ≥2.0 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established an azithromycin resistance breakpoint for *N. gonorrhoeae*.

Figure G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	1 (0.7)	0 (0.0)	1
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	1 (2.9)	0 (0.0)	0 (0.0)	1

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
 Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	1 (0.7)	0 (0.0)	1
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	1 (2.9)	0 (0.0)	0 (0.0)	1

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	8 (14.0)	10 (8.1)	0 (0.0)	18
Genital	2021	4 (7.3)	6 (4.0)	0 (0.0)	10
Genital	2022	0 (0.0)	6 (3.4)	0 (0.0)	6
Pharyngeal	2020	2 (22.2)	0 (0.0)	0 (0.0)	2
Pharyngeal	2021	1 (33.3)	0 (0.0)	0 (0.0)	1
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	1 (5.0)	0 (0.0)	0 (0.0)	1
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	2 (5.9)	0 (0.0)	0 (0.0)	2

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
Azithromycin elevated MIC  $\geq 2.0$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	29 (50.9)	57 (46.3)	2 (66.7)	88
Genital	2021	22 (40.0)	70 (46.4)	2 (25.0)	94
Genital	2022	35 (46.1)	51 (28.8)	0 (0.0)	86
Pharyngeal	2020	4 (44.4)	0 (0.0)	0 (0.0)	4
Pharyngeal	2021	3 (100.0)	0 (0.0)	1 (100.0)	4
Pharyngeal	2022	3 (50.0)	0 (0.0)	0 (0.0)	3
Rectal	2020	8 (40.0)	1 (100.0)	0 (0.0)	9
Rectal	2021	8 (47.1)	0 (0.0)	0 (0.0)	8
Rectal	2022	16 (47.1)	0 (0.0)	0 (0.0)	16

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MIC ≥1.0 µg/mL.

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.


Figure A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2022



Site of Infection	Patient Gender	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	15 (6.4)	47 (20.0)	55 (23.4)	45 (19.1)	24 (10.2)	10 (4.3)	14 (6.0)	15 (6.4)	6 (2.6)	2 (0.9)	2 (0.9)	235
Genital	Female	4 (8.2)	15 (30.6)	11 (22.4)	8 (16.3)	2 (4.1)	3 (6.1)	3 (6.1)	1 (2.0)	1 (2.0)	1 (2.0)	0 (0)	49
Pharyngeal	Male	2 (3.1)	20 (31.3)	16 (25.0)	11 (17.2)	5 (7.8)	2 (3.1)	4 (6.3)	2 (3.1)	1 (1.6)	1 (1.6)	0 (0)	64
Pharyngeal	Female	4 (11.8)	11 (32.4)	5 (14.7)	6 (17.6)	2 (5.9)	3 (8.8)	1 (2.9)	1 (2.9)	1 (2.9)	0 (0)	0 (0)	34
Rectal	Male	3 (4.5)	24 (36.4)	15 (22.7)	10 (15.2)	7 (10.6)	0 (0)	3 (4.5)	0 (0)	0 (0)	1 (1.5)	3 (4.5)	66
Rectal	Female	1 (20.0)	2 (40.0)	1 (20.0)	1 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	5

Cases with unknown age were excluded.


Figure B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2022



Site of Infection	Patient Gender	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	3 (1.3)	84 (35.7)	0 (0)	35 (14.9)	105 (44.7)	3 (1.3)	5 (2.1)	235
Genital	Female	2 (4.1)	1 (2.0)	6 (12.2)	1 (2.0)	11 (22.4)	26 (53.1)	0 (0)	2 (4.1)	49
Pharyngeal	Male	0 (0)	0 (0)	6 (9.4)	0 (0)	21 (32.8)	37 (57.8)	0 (0)	0 (0)	64
Pharyngeal	Female	1 (2.9)	1 (2.9)	6 (17.6)	0 (0)	12 (35.3)	14 (41.2)	0 (0)	0 (0)	34
Rectal	Male	2 (3.0)	1 (1.5)	4 (6.1)	0 (0)	20 (30.3)	37 (56.1)	2 (3.0)	0 (0)	66
Rectal	Female	1 (20.0)	0 (0)	1 (20.0)	0 (0)	2 (40.0)	1 (20.0)	0 (0)	0 (0)	5

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Figure C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2020-2022




Site of Infection	Year	MSM	MSW	Women	Total
Genital	2020	91	206	80	377
Genital	2021	76	204	44	324
Genital	2022	69	166	49	284
Pharyngeal	2020	34	10	14	58
Pharyngeal	2021	31	12	25	68
Pharyngeal	2022	45	19	34	98
Rectal	2020	59	1	6	66
Rectal	2021	46	4	1	51
Rectal	2022	66	0	5	71

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.



Figure D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2020-2022



Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	215 (56.6)	115 (30.3)	31 (8.2)	14 (3.7)	5 (1.3)	0 (0.0)	0 (0.0)	380
Genital	2021	265 (81.8)	47 (14.5)	3 (0.9)	9 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)	324
Genital	2022	197 (69.4)	72 (25.4)	7 (2.5)	6 (2.1)	2 (0.7)	0 (0.0)	0 (0.0)	284
Pharyngeal	2020	19 (32.8)	28 (48.3)	10 (17.2)	1 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	58
Pharyngeal	2021	49 (70.0)	14 (20.0)	1 (1.4)	5 (7.1)	1 (1.4)	0 (0.0)	0 (0.0)	70
Pharyngeal	2022	73 (74.5)	21 (21.4)	2 (2.0)	2 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	98
Rectal	2020	25 (37.9)	35 (53.0)	6 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	66
Rectal	2021	41 (80.4)	8 (15.7)	1 (2.0)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Rectal	2022	49 (69.0)	20 (28.2)	1 (1.4)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	71


GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Figure E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2020-2022



Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	214 (56.3)	117 (30.8)	42 (11.1)	7 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	380
Genital	2021	227 (70.1)	78 (24.1)	18 (5.6)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	324
Genital	2022	192 (67.6)	83 (29.2)	7 (2.5)	2 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	284
Pharyngeal	2020	20 (34.5)	25 (43.1)	12 (20.7)	1 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	58
Pharyngeal	2021	43 (61.4)	18 (25.7)	6 (8.6)	3 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	70
Pharyngeal	2022	62 (63.3)	30 (30.6)	6 (6.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	98
Rectal	2020	29 (43.9)	26 (39.4)	10 (15.2)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	66
Rectal	2021	33 (64.7)	14 (27.5)	4 (7.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Rectal	2022	49 (69.0)	20 (28.2)	2 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	71


GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Figure F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2020-2022



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2020	45 (11.8)	264 (69.5)	19 (5.0)	37 (9.7)	11 (2.9)	2 (0.5)	1 (0.3)	1 (0.3)	380
Genital	2021	48 (14.8)	216 (66.7)	20 (6.2)	32 (9.9)	5 (1.5)	1 (0.3)	0 (0.0)	2 (0.6)	324
Genital	2022	59 (20.8)	164 (57.7)	15 (5.3)	36 (12.7)	8 (2.8)	0 (0.0)	1 (0.4)	1 (0.4)	284
Pharyngeal	2020	4 (6.9)	42 (72.4)	5 (8.6)	5 (8.6)	1 (1.7)	0 (0.0)	0 (0.0)	1 (1.7)	58
Pharyngeal	2021	10 (14.3)	37 (52.9)	8 (11.4)	12 (17.1)	3 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	70
Pharyngeal	2022	20 (20.4)	52 (53.1)	6 (6.1)	12 (12.2)	4 (4.1)	1 (1.0)	2 (2.0)	1 (1.0)	98
Rectal	2020	8 (12.1)	40 (60.6)	6 (9.1)	10 (15.2)	2 (3.0)	0 (0.0)	0 (0.0)	0 (0.0)	66
Rectal	2021	4 (7.8)	33 (64.7)	4 (7.8)	9 (17.6)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Rectal	2022	7 (9.9)	44 (62.0)	2 (2.8)	15 (21.1)	3 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	71


GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; CLSI Non-susceptible = azithromycin MIC ≥2.0 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established an azithromycin resistance breakpoint for *N. gonorrhoeae*.

Figure G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	3 (1.5)	2 (2.5)	5
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	2 (1.2)	0 (0.0)	2
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	1 (4.0)	1
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g}/\text{mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	2 (2.2)	4 (1.9)	9 (11.3)	15
Genital	2021	3 (3.9)	4 (2.0)	1 (2.3)	8
Genital	2022	3 (4.3)	5 (3.0)	2 (4.1)	10
Pharyngeal	2020	1 (2.9)	0 (0.0)	1 (7.1)	2
Pharyngeal	2021	0 (0.0)	0 (0.0)	3 (12.0)	3
Pharyngeal	2022	2 (4.4)	2 (10.5)	4 (11.8)	8
Rectal	2020	2 (3.4)	0 (0.0)	0 (0.0)	2
Rectal	2021	1 (2.2)	0 (0.0)	0 (0.0)	1
Rectal	2022	2 (3.0)	0 (0.0)	1 (20.0)	3

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
Azithromycin elevated MIC  $\geq 2.0$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	40 (44.0)	49 (23.8)	17 (21.3)	106
Genital	2021	27 (35.5)	65 (31.9)	14 (31.8)	106
Genital	2022	26 (37.7)	38 (22.9)	15 (30.6)	79
Pharyngeal	2020	21 (61.8)	2 (20.0)	7 (50.0)	30
Pharyngeal	2021	12 (38.7)	3 (25.0)	3 (12.0)	18
Pharyngeal	2022	19 (42.2)	10 (52.6)	8 (23.5)	37
Rectal	2020	22 (37.3)	0 (0.0)	1 (16.7)	23
Rectal	2021	26 (56.5)	3 (75.0)	0 (0.0)	29
Rectal	2022	25 (37.9)	0 (0.0)	1 (20.0)	26

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
 Ciprofloxacin resistance = MIC ≥1.0 µg/mL.

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2022




Site of Infection	Patient Gender	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	5 (9.8)	4 (7.8)	18 (35.3)	11 (21.6)	5 (9.8)	5 (9.8)	1 (2.0)	1 (2.0)	0 (0)	0 (0)	1 (2.0)	51
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	0 (0)	1 (33.3)	2 (66.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	2 (28.6)	0 (0)	1 (14.3)	1 (14.3)	0 (0)	1 (14.3)	0 (0)	1 (14.3)	0 (0)	1 (14.3)	7
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.




Figure B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2022



Site of Infection	Patient Gender	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	2 (3.9)	36 (70.6)	0 (0)	12 (23.5)	1 (2.0)	0 (0)	0 (0)	51
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	1 (33.3)	0 (0)	2 (66.7)	0 (0)	0 (0)	0 (0)	3
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	2 (28.6)	0 (0)	5 (71.4)	0 (0)	0 (0)	0 (0)	7
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2020-2022



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2020	11	35	0	46
Genital	2021	7	32	0	39
Genital	2022	20	29	0	49
Pharyngeal	2020	2	1	0	3
Pharyngeal	2021	3	1	0	4
Pharyngeal	2022	2	0	0	2
Rectal	2020	2	0	0	2
Rectal	2021	9	0	2	11
Rectal	2022	7	0	0	7

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2020-2022



Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	17 (37.0)	21 (45.7)	4 (8.7)	0 (0.0)	4 (8.7)	0 (0.0)	0 (0.0)	46
Genital	2021	26 (66.7)	7 (17.9)	2 (5.1)	4 (10.3)	0 (0.0)	0 (0.0)	0 (0.0)	39
Genital	2022	41 (80.4)	5 (9.8)	3 (5.9)	2 (3.9)	0 (0.0)	0 (0.0)	0 (0.0)	51
Pharyngeal	2020	3 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	2021	2 (40.0)	1 (20.0)	0 (0.0)	2 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	2 (66.7)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2020	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2021	6 (54.5)	2 (18.2)	0 (0.0)	3 (27.3)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	5 (71.4)	2 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7


GISP Alert Value = cefixime MIC  $\geq 0.25$  µg/mL; CLSI Non-susceptible = cefixime MIC  $\geq 0.5$  µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Figure E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2020-2022



Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	25 (54.3)	15 (32.6)	6 (13.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	46
Genital	2021	29 (74.4)	7 (17.9)	3 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	39
Genital	2022	42 (82.4)	6 (11.8)	2 (3.9)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Pharyngeal	2020	3 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	2021	3 (60.0)	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	3 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2020	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2021	4 (36.4)	6 (54.5)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	5 (71.4)	2 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7


GISP Alert Value = ceftriaxone MIC  $\geq 0.125$  µg/mL; CLSI Non-susceptible = ceftriaxone MIC  $\geq 0.5$  µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Figure F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2020-2022



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2020	5 (10.9)	19 (41.3)	4 (8.7)	15 (32.6)	3 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	46
Genital	2021	6 (15.4)	26 (66.7)	2 (5.1)	3 (7.7)	1 (2.6)	1 (2.6)	0 (0.0)	0 (0.0)	39
Genital	2022	8 (15.7)	26 (51.0)	9 (17.6)	7 (13.7)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Pharyngeal	2020	0 (0.0)	2 (66.7)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	2021	1 (20.0)	3 (60.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	1 (33.3)	1 (33.3)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2020	0 (0.0)	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2021	1 (9.1)	8 (72.7)	1 (9.1)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	2 (28.6)	3 (42.9)	0 (0.0)	0 (0.0)	2 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	7


GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; CLSI Non-susceptible = azithromycin MIC ≥2.0 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established an azithromycin resistance breakpoint for *N. gonorrhoeae*.

Figure G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	1 (9.1)	3 (8.6)	0 (0.0)	4
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	3 (8.6)	0 (0.0)	3
Genital	2021	0 (0.0)	2 (6.3)	0 (0.0)	2
Genital	2022	0 (0.0)	1 (3.4)	0 (0.0)	1
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	2 (28.6)	0 (0.0)	0 (0.0)	2

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
Azithromycin elevated MIC  $\geq 2.0$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.



Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	1 (9.1)	3 (8.6)	0 (0.0)	4
Genital	2021	4 (57.1)	10 (31.3)	0 (0.0)	14
Genital	2022	5 (25.0)	7 (24.1)	0 (0.0)	12
Pharyngeal	2020	2 (100.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	2021	1 (33.3)	0 (0.0)	0 (0.0)	1
Pharyngeal	2022	1 (50.0)	0 (0.0)	0 (0.0)	1
Rectal	2020	2 (100.0)	0 (0.0)	0 (0.0)	2
Rectal	2021	4 (44.4)	0 (0.0)	1 (50.0)	5
Rectal	2022	1 (14.3)	0 (0.0)	0 (0.0)	1

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MIC ≥1.0 µg/mL.

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.


Figure A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2022



Site of Infection	Patient Gender	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	2 (11.1)	1 (5.6)	3 (16.7)	4 (22.2)	4 (22.2)	1 (5.6)	3 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	18
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	1 (25.0)	1 (25.0)	2 (50.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	1 (33.3)	0 (0)	1 (33.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (33.3)	0 (0)	0 (0)	3
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.


Figure B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2022



Site of Infection	Patient Gender	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	0 (0)	7 (38.9)	0 (0)	6 (33.3)	4 (22.2)	0 (0)	1 (5.6)	18
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (100.0)	0 (0)	0 (0)	4
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	1 (33.3)	2 (66.7)	0 (0)	0 (0)	3
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Figure C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2020-2022




Site of Infection	Year	MSM	MSW	Women	Total
Genital	2020	59	42	1	102
Genital	2021	84	46	4	134
Genital	2022	7	11	0	18
Pharyngeal	2020	12	2	3	17
Pharyngeal	2021	26	0	4	30
Pharyngeal	2022	4	0	0	4
Rectal	2020	22	0	1	23
Rectal	2021	29	0	1	30
Rectal	2022	3	0	0	3

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2020-2022



Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	77 (74.0)	24 (23.1)	2 (1.9)	1 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	104
Genital	2021	87 (64.4)	39 (28.9)	7 (5.2)	2 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	135
Genital	2022	14 (77.8)	4 (22.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Pharyngeal	2020	15 (83.3)	3 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Pharyngeal	2021	18 (60.0)	11 (36.7)	0 (0.0)	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)	30
Pharyngeal	2022	1 (25.0)	1 (25.0)	0 (0.0)	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2020	20 (83.3)	2 (8.3)	1 (4.2)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	24
Rectal	2021	18 (58.1)	9 (29.0)	1 (3.2)	3 (9.7)	0 (0.0)	0 (0.0)	0 (0.0)	31
Rectal	2022	2 (66.7)	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	3


GISP Alert Value = cefixime MIC  $\geq 0.25$  µg/mL; CLSI Non-susceptible = cefixime MIC  $\geq 0.5$  µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Figure E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2020-2022



Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2020	68 (65.4)	29 (27.9)	7 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	104
Genital	2021	77 (57.0)	51 (37.8)	7 (5.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	135
Genital	2022	11 (61.1)	7 (38.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Pharyngeal	2020	9 (50.0)	7 (38.9)	2 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Pharyngeal	2021	18 (60.0)	10 (33.3)	2 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	30
Pharyngeal	2022	1 (25.0)	2 (50.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2020	15 (62.5)	6 (25.0)	3 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24
Rectal	2021	18 (58.1)	9 (29.0)	4 (12.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	31
Rectal	2022	2 (66.7)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3


GISP Alert Value = ceftriaxone MIC  $\geq 0.125$  µg/mL; CLSI Non-susceptible = ceftriaxone MIC  $\geq 0.5$  µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Figure F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2020-2022



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2020	8 (7.7)	71 (68.3)	10 (9.6)	3 (2.9)	10 (9.6)	1 (1.0)	1 (1.0)	0 (0.0)	104
Genital	2021	12 (8.9)	90 (66.7)	7 (5.2)	13 (9.6)	13 (9.6)	0 (0.0)	0 (0.0)	0 (0.0)	135
Genital	2022	5 (27.8)	11 (61.1)	1 (5.6)	0 (0.0)	1 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	18
Pharyngeal	2020	0 (0.0)	12 (66.7)	2 (11.1)	2 (11.1)	2 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	18
Pharyngeal	2021	4 (13.3)	18 (60.0)	1 (3.3)	5 (16.7)	2 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	30
Pharyngeal	2022	1 (25.0)	3 (75.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2020	2 (8.3)	14 (58.3)	2 (8.3)	3 (12.5)	3 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	24
Rectal	2021	0 (0.0)	23 (74.2)	2 (6.5)	2 (6.5)	4 (12.9)	0 (0.0)	0 (0.0)	0 (0.0)	31
Rectal	2022	0 (0.0)	2 (66.7)	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	3


GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; CLSI Non-susceptible = azithromycin MIC ≥2.0 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of the end of 2022, the CLSI has not established an azithromycin resistance breakpoint for *N. gonorrhoeae*.

Figure G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.



Figure H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2020-2022




Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	10 (16.9)	2 (4.8)	0 (0.0)	12
Genital	2021	7 (8.3)	4 (8.7)	1 (25.0)	12
Genital	2022	0 (0.0)	1 (9.1)	0 (0.0)	1
Pharyngeal	2020	2 (16.7)	0 (0.0)	0 (0.0)	2
Pharyngeal	2021	2 (7.7)	0 (0.0)	0 (0.0)	2
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	3 (13.6)	0 (0.0)	0 (0.0)	3
Rectal	2021	4 (13.8)	0 (0.0)	0 (0.0)	4
Rectal	2022	1 (33.3)	0 (0.0)	0 (0.0)	1

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.  
Azithromycin elevated MIC  $\geq 2.0$   $\mu\text{g/mL}$ .

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.

Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2020-2022



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2020	31 (52.5)	17 (40.5)	0 (0.0)	48
Genital	2021	38 (45.2)	19 (41.3)	0 (0.0)	57
Genital	2022	5 (71.4)	7 (63.6)	0 (0.0)	12
Pharyngeal	2020	7 (58.3)	1 (50.0)	2 (66.7)	10
Pharyngeal	2021	15 (57.7)	0 (0.0)	0 (0.0)	15
Pharyngeal	2022	3 (75.0)	0 (0.0)	0 (0.0)	3
Rectal	2020	12 (54.5)	0 (0.0)	0 (0.0)	12
Rectal	2021	12 (41.4)	0 (0.0)	0 (0.0)	12
Rectal	2022	2 (66.7)	0 (0.0)	0 (0.0)	2

MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance = MIC  $\geq$  1.0  $\mu$ g/mL.

Data presented do not include isolates collected from participants identifying as transgender, nonbinary, or unknown/missing gender of sex partner.